Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with ...

The GLP-1 compound drug sold by Hims and Hers is not approved by the FDA and its Super Bowl ad fails to list any risks ...

Study results show that genetic sensitivity to stress was linked to a 49% higher risk of lung cancer in people of European ...

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...

PEPFAR, the main U.S.-funded global AIDS program was given a waiver from the foreign aid freeze, but there is still ...

Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...

The technology to leverage healthcare data exists. The problem, according to Highlander Health, is outdated structures and ...

The biggest challenge in training the next generation of respiratory therapists is getting them to engage in "critical ...

Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...

Native Americans face the longest travel times, even after accounting for distances in rural areas, according to results of a ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Treosulfan (Grafapex) was approved in Canada in June 2021 for the same use and is marketed under the brand name Trecondyv.